REG - Ergomed plc - Notice of Results <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

29/10/2014 08:04

RNS Number : 7940Q
Ergomed plc
04 September 2014
Ergomed plc Notice of Interim Results
Guildford, UK - 4th September 2014: Ergomed plc, (LSE:ERGO) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will announce its interim results for the six months ended 30th June, 2014 on 30th September, 2014.
Dr. Miroslav Reljanovic, Chief Executive Officer and Neil Clark, Chief Financial Officer will host a presentation for analysts at 9am at Oriel Securities Limited offices, 150 Cheapside, London, EC2V 6ET.
For further information, please contact:
Hume Brophy
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
ergomed@humebrophy.com
Oriel Securities 
NOMAD/Broker to the Company
Juliet Thompson, Jonathan Senior 
Tel: +44 207 710 7600
ENDS
About Ergomed 
Founded in 1997, Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: http://ergomedgroup.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORUGUMWBUPCGMW